Skip to main content
SpringerLink
Log in

Drugs and prolactin

Pituitary volume 11, pages 209–218 (2008)Cite this article

Abstract

Medications commonly cause hyperprolactinemia and their use must be differentiated from pathologic causes. The most common medications to cause hyperprolactinemia are the antipsychotic agents, although some of the newer atypical antipsychotics do not do so. Other medications causing hyperprolactinemia include antidepressants, antihypertensive agents, and drugs which increase bowel motility. Often, the medication-induced hyperprolactinemia is symptomatic, causing galactorrhea, menstrual disturbance, and erectile dysfunction. In the individual patient, it is important differentiate hyperprolactinemia due to a medication from a structural lesion in the hypothalamic–pituitary area. This can be done by stopping the medication temporarily to determine if the prolactin (PRL) levels return to normal, switching to another medication in the same class which does not cause hyperprolactinemia (in consultation with the patient’s physician and/or psychiatrist), or by performing an MRI or CT scan. If the hyperprolactinemia is symptomatic, management strategies include switching to an alternative medication which does not cause hyperprolactinemia, using estrogen/testosterone replacement, or cautiously adding a dopamine agonist.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Molitch ME (2001) Disorders of prolactin secretion. Endocrinol Metab Clin N Amer 30:585–610. doi:10.1016/S0889-8529(05)70203-6

    Article  PubMed  CAS  Google Scholar 

  2. Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 17:213–223

    PubMed  CAS  Google Scholar 

  3. Wieck A, Haddad P (2002) Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324:250–252. Medline. doi:10.1136/bmj.324.7332.250

    Article  PubMed  Google Scholar 

  4. Maguire A (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56–62. Medline

    PubMed  CAS  Google Scholar 

  5. Rubin RT, Hays SE (1980) The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 5:121–137. Medline. doi:10.1016/0306-4530(80)90015-3

    Article  PubMed  CAS  Google Scholar 

  6. Langer G, Sachar EJ (1977) Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine. Psychoneuroendocrinology 2:373–378. Medline. doi:10.1016/0306-4530(77)90007-5

    Article  PubMed  CAS  Google Scholar 

  7. Langer G, Sachar EJ, Halpern FS (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine. J Clin Endocrinol Metab 45:996–1002. Medline

    PubMed  CAS  Google Scholar 

  8. Spitzer M, Siajjad R, Benjamin F (1998) Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 91:693–695. Medline. doi:10.1016/S0029-7844(98)00066-0

    Article  PubMed  CAS  Google Scholar 

  9. Meltzer HY, Fang VS (1976) Serum prolactin levels in schizophrenia—effect of antipsychotic drugs: a preliminary report. In: Sachar J (ed) Hormones, behavior, and psychopathology. Raven Press, New York, NY, pp 177–190

    Google Scholar 

  10. De Rivera JL, Lal S, Ettigi P et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282. Medline

    Article  CAS  Google Scholar 

  11. Pollock A, McLaren EH (1998) Serum prolactin concentrations in patients taking neuroleptic drugs. Clin Endocrinol (Oxf) 49:513–516. Medline. doi:10.1046/j.1365-2265.1998.00569.x

    Article  CAS  Google Scholar 

  12. Smith S, Wheeler MJ, Murray R et al (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22:109–114. Medline. doi:10.1097/00004714-200204000-00002

    Article  PubMed  CAS  Google Scholar 

  13. Zelaschi N, Delucchi GA, Rodriguez JL (1996) High prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 39:900–901. doi:10.1016/0006-3223(95)00589-7

    Article  PubMed  CAS  Google Scholar 

  14. Kleinberg DL, Davis JM, deCoster R et al (1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57–61. Medline. doi:10.1097/00004714-199902000-00011

    Article  PubMed  CAS  Google Scholar 

  15. Kinon BJ, Gilmore JA, Liu H et al (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28:55–68. Medline. doi:10.1016/S0306-4530(02)00127-0

    Article  PubMed  CAS  Google Scholar 

  16. Hamner M (2002) The effect of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 14:163–173. Medline. doi:10.1023/A:1021138603935

    PubMed  Google Scholar 

  17. Kinon BJ, Gilmore JA, Liu H et al (2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28:69–82. Medline. doi:10.1016/S0306-4530(02)00128-2

    Article  PubMed  CAS  Google Scholar 

  18. Kearns AE, Goff DC, Hayden DL et al (2000) Risperidone-associated hyperprolactinemia. Endocr Pract 6:425–429. Medline

    PubMed  CAS  Google Scholar 

  19. David SR, Taylor CC, Kinon BJ et al (2000) The effect of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085–1096. Medline. doi:10.1016/S0149-2918(00)80086-7

    Article  PubMed  CAS  Google Scholar 

  20. Becker D, Liver O, Mester R et al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64:761–766. Medline

    PubMed  CAS  Google Scholar 

  21. Findling RL, Kusumakar V, Daneman D et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362–1369. Medline

    Article  PubMed  CAS  Google Scholar 

  22. Volavka J, Czobor P, Cooper TB et al (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57–61. Medline

    PubMed  CAS  Google Scholar 

  23. Holzer L, Eap CB (2006) Risperidone-induced symptomatic hyperprolactinemia in adolescents. J Clin Psychopharmacol 26:167–171. Medline. doi:10.1097/01.jcp.0000203194.58087.9a

    Article  PubMed  CAS  Google Scholar 

  24. Pandurangi AK, Narasimhachari N, Blackard WG et al (1989) Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 50:379–381. Medline

    PubMed  CAS  Google Scholar 

  25. Breier AF, Malhotra AK, Su T-P et al (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294–298. Medline

    PubMed  CAS  Google Scholar 

  26. Turrone P, Kapur S, Seeman MV et al (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133–135. Medline. doi:10.1176/appi.ajp.159.1.133

    Article  PubMed  Google Scholar 

  27. Crawford AM, Beasley CM Jr, Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26:41–54. Medline. doi:10.1016/S0920-9964(97)00036-4

    Article  PubMed  CAS  Google Scholar 

  28. Kim K-S, Pae C-U, Hae J-H et al (2002) Effects of olanzapine on prolactin levels of female patients treated with schizophrenia treated with risperidone. J Clin Psychiatry 63:408–413. Medline

    PubMed  CAS  Google Scholar 

  29. Hamner MB, Arvanitis LA, Miller BG et al (1996) Plasma prolactin in schizophrenia subjects treated with SeroquelTM (ICI 204,636). Psychopharmacol Bull 32:107–110. Medline

    PubMed  CAS  Google Scholar 

  30. Atmaca M, Kuloglu M, Tezcan E et al (2002) Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 33:562–565. Medline. doi:10.1016/S0188-4409(02)00403-4

    Article  PubMed  CAS  Google Scholar 

  31. Goff DC, Posever T, Herz L et al (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296–304. Medline. doi:10.1097/00004714-199808000-00009

    Article  PubMed  CAS  Google Scholar 

  32. Casey DE, Carson WH, Saha AR, Aripiprazole Study Group et al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399. Medline

    CAS  Google Scholar 

  33. Keck PE Jr, Marcus R, Tourkodimitris S et al (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651–1568. Medline. doi:10.1176/appi.ajp.160.9.1651

    Article  PubMed  Google Scholar 

  34. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38. Medline

    PubMed  Google Scholar 

  35. Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607–1618. Medline

    PubMed  CAS  Google Scholar 

  36. Gründer. Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications. Occupancy is not just antagonism. Arch Gen Psychiatry 60:974–977. Medline. doi:10.1001/archpsyc.60.10.974

    Article  Google Scholar 

  37. Cutler AJ (2003) Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28:69–82. Medline. doi:10.1016/S0306-4530(02)00113-0

    Article  PubMed  CAS  Google Scholar 

  38. Knegtering H, van der Mooler AEGM, Castelein S et al (2003) What are the effects of antipsychotics on sexual dysfunction and endocrine functioning. Psychoneuroendocrinology 28:109–123. Medline. doi:10.1016/S0306-4530(02)00130-0

    Article  PubMed  CAS  Google Scholar 

  39. Brunelleschi S, Zeppegno P, Risso F et al (2003) Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol Res 48:405–409. Medline. doi:10.1016/S1043-6618(03)00174-9

    Article  PubMed  CAS  Google Scholar 

  40. Knegtering R, Castelein S, Bous H et al (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24:56–61. Medline. doi:10.1097/01.jcp.0000106220.36344.04

    Article  PubMed  CAS  Google Scholar 

  41. Ataya K, Abbasi A, Mercado A et al (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876–881. Medline

    PubMed  CAS  Google Scholar 

  42. Dunbar F, Kusumakar V, Daneman D et al (2004) Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918–920. Medline. doi:10.1176/appi.ajp.161.5.918

    Article  PubMed  Google Scholar 

  43. Meltzer HY, Fang VS, Tricou BJ et al (1982) Effect of antidepressants on neuroendocrine axis in humans. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: clinical practice. Raven Press, New York, NY, pp 303–316

    Google Scholar 

  44. Price LH, Charney DS, Delgado PL et al (1989) Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625–631. Medline

    PubMed  CAS  Google Scholar 

  45. Jones RB, Luscombe DK, Groom GV (1977) Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J 53(Suppl 4):166–71

    PubMed  CAS  Google Scholar 

  46. Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11:851–856. Medline

    PubMed  CAS  Google Scholar 

  47. Slater SL, Lipper S, Shiling DJ et al (1977) Elevation of plasma-prolactin by monoamine-oxidase inhibitors. Lancet 2:275–276. Medline. doi:10.1016/S0140-6736(77)90956-4

    Article  PubMed  CAS  Google Scholar 

  48. Price LH, Charney DS, Heninger GR (1985) Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 37:809–818. Medline. doi:10.1016/0024-3205(85)90515-6

    Article  PubMed  CAS  Google Scholar 

  49. Cohen MA, Davies PH (1998) Drug therapy and hyperprolactinaemia. Adverse Drug React Bull 190:723–726

    Article  Google Scholar 

  50. Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147–152. Medline

    PubMed  CAS  Google Scholar 

  51. Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11:345–348. Medline

    Article  PubMed  CAS  Google Scholar 

  52. Amsterdam JD, Garcia-España F, Goodman D et al (1997) Breast enlargement during chronic antidepressant therapy. J Affect Dis 46:151–156. Medline. doi:10.1016/S0165-0327(97)00086-4

    Article  PubMed  CAS  Google Scholar 

  53. Mück-Šeler D, Pivac N, Šagud M et al (2002) The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 26:1235–1243. Medline. doi:10.1016/S0278-5846(02)00259-2

    Article  PubMed  Google Scholar 

  54. Laine K, Anttila M, Heinonen E et al (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20:419–433. Medline. doi:10.1097/00002826-199710000-00006

    Article  PubMed  CAS  Google Scholar 

  55. Shlik J, Aluoja A, Vasar V et al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340. Medline

    PubMed  CAS  Google Scholar 

  56. Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 137:201–202. Medline. doi:10.1007/s002130050610

    Article  CAS  Google Scholar 

  57. Šagud M, Pivac N, Mück-Šeler D et al (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45:139–143. Medline. doi:10.1159/000054954

    Article  PubMed  Google Scholar 

  58. Spigset O, Mjöndal T (1997) The effect of fluvoxamine on serum prolactin, serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 17:292–297. Medline. doi:10.1097/00004714-199708000-00009

    Article  PubMed  CAS  Google Scholar 

  59. Iancu I, Ratzoni G, Weitzman A et al (1992) More fluoxetine experience. J Am Acad Child Adolesc Psychiatry 31:755–756. Medline. doi:10.1097/00004583-199207000-00032

    Article  PubMed  CAS  Google Scholar 

  60. Peterson MC (2001) Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76:215–216. Medline

    PubMed  CAS  Google Scholar 

  61. Emiliano ABF, Fudge JL (2004) From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacol 29:833–846. doi:10.1038/sj.npp.1300412

    Article  CAS  Google Scholar 

  62. Walsh AE, Cowen PJ (1994) Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 14:268–273. Medline

    PubMed  CAS  Google Scholar 

  63. Whiteman PD, Peck AW, Fowle AS et al (1983) Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 44:209–210. Medline

    PubMed  CAS  Google Scholar 

  64. Bonuccelli U, Murialdo G, Martino E et al (1985) Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects. Clin Neuropharmacol 8:165–174. Medline. doi:10.1097/00002826-198506000-00006

    Article  PubMed  CAS  Google Scholar 

  65. Price LH, Charney DS, Heninger GR (1988) Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Res 24:165–175. Medline. doi:10.1016/0165-1781(88)90059-5

    Article  PubMed  CAS  Google Scholar 

  66. Otani K, Yasui N, Kaneko S et al (1995) Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol 10:115–117. Medline. doi:10.1097/00004850-199506000-00009

    Article  PubMed  CAS  Google Scholar 

  67. Batürk M, Karaaslan F, Eşel E et al (2001) Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:315–322. Medline. doi:10.1016/S0278-5846(00)00165-2

    Article  Google Scholar 

  68. Tolis G, Hickey J, Guyda H (1975) Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 41:797–800. Medline

    PubMed  CAS  Google Scholar 

  69. Zis AP, Haskett RF, Albala AA et al (1984) Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 9:423–427.Medline. doi:10.1016/0306-4530(84)90050-7

    Article  PubMed  CAS  Google Scholar 

  70. Chan V, Wang C, Yeung TT (1979) Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men. Clin Endocrinol (Oxf) 10:557–565. Medline

    Article  CAS  Google Scholar 

  71. Afrasiabi MA, Flomm M, Friedlander H et al (1979) Endocrine studies in heroin addicts. Psychoneuroendocrinology 4:145–153. Medline. doi:10.1016/0306-4530(79)90028-3

    Article  PubMed  CAS  Google Scholar 

  72. Bart G, Borg L, Schluger JH et al (2003) Suppressed prolactin response to dynorphin A1–13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 306:581–587. Medline. doi:10.1124/jpet.103.050682

    Article  PubMed  CAS  Google Scholar 

  73. Panerai AE, Petraglia F, Sacerdote P et al (1985) Mainly μ-opiate receptors are involved in luteinizing hormone and prolactin secretion. Endocrinology 117:1096–1099. Medline

    PubMed  CAS  Google Scholar 

  74. Pfeiffer A, Braun S, Mann K (1986) Anterior pituitary hormone responses to a k-opioid agonist in man. J Clin Endocrinol Metab 62:181–185. Medline

    PubMed  CAS  Google Scholar 

  75. Leadem CA, Yagenova SV (1987) Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45:109–117. Medline

    Article  PubMed  CAS  Google Scholar 

  76. Van Vugt DA, Bruni JF, Sylvester PW et al (1979) Interaction between opiates and hypothalamic dopamine on prolactin release. Life Sci 24:2361–2368. MEdline. doi:10.1016/0024-3205(79)90534-4

    Article  PubMed  Google Scholar 

  77. Van Loon GR, Ho D, Kim C (1980) ß-endorphin-induced decrease in hypothalamic dopamine turnover. Endocrinology 106:76–80. Medline

    PubMed  Google Scholar 

  78. Gudelsky GA, Porter JC (1979) Morphine- and opioid peptide-induced inhibition of the release of dopamine from tuberoinfundibular neurons. Life Sci 25:1697–1702. Medline. doi:10.1016/0024-3205(79)90411-9

    Article  PubMed  CAS  Google Scholar 

  79. Lee MA, Bowers MM, Nash JF et al (1990) Neuroendocrine measures of dopaminergic function in chronic cocaine users. Psychiatry Res 33:151–159. Medline. doi:10.1016/0165-1781(90)90069-H

    Article  PubMed  CAS  Google Scholar 

  80. Mendelson JH, Mello NK, Teoh SK et al (1989) Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256–1260. Medline

    PubMed  CAS  Google Scholar 

  81. Maestri E, Camellini L, Rossi G et al (1985) Effects of five days verapamil administration on serum GH and PRL levels. Horm Metab Res 17:482. Medline

    Article  PubMed  CAS  Google Scholar 

  82. Kamal TJ, Molitch ME (1992) Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-DOPA and bromocriptine. Am J Med Sci 304:289–293. Medline. doi:10.1097/00000441-199211000-00004

    Article  PubMed  CAS  Google Scholar 

  83. Kelley SR, Kamal TJ, Molitch ME (1996) Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 270 (Endocrinol Metab 33):E96–E100

  84. Gluskin LE, Strasberg B, Shah JH (1981) Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med 95:66–67. Medline

    PubMed  CAS  Google Scholar 

  85. Fearrington EL, Rand CH, Rose JD (1983) Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 51:1446. Medline. doi:10.1016/0002-9149(83)90336-3

    Article  Google Scholar 

  86. Romeo JH, Dombrowski R, Kwak YS et al (1996) Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 45:571–575. Medline. doi:10.1046/j.1365-2265.1996.00859.x

    Article  CAS  Google Scholar 

  87. Steiner J, Cassar J, Mashiter K et al (1976) Effect of methyldopa on prolactin and growth hormone. BMJ 1:1186–1188. Medline

    PubMed  CAS  Google Scholar 

  88. Lee PA, Kelly MR, Wallin JD (1976) Increased prolactin levels during reserpine treatment of hypertensive patients. JAMA 235:2316–2317. Medline. doi:10.1001/jama.235.21.2316

    Article  PubMed  CAS  Google Scholar 

  89. Winer LM, Molteni A, Molitch ME (1990) Effect of angiotensin—converting enzyme inhibition on pituitary hormone response to insulin—induced hypoglycemia in humans. J Clin Endocrinol Metab 71:256–259. Medline

    PubMed  CAS  Google Scholar 

  90. Barbieri C, Larovere MT, Mariotti G et al (1982) Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 16:615–619. Medline

    Article  CAS  Google Scholar 

  91. Aono T, Shioji T, Kinugasa T et al (1978) Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab 47:675–680. Medline

    Article  PubMed  CAS  Google Scholar 

  92. Tamagna EI, Lane WS, Hershman JM et al (1979) Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res 11:161–169. Medline

    Article  PubMed  CAS  Google Scholar 

  93. Fujino T, Kato H, Yamashita S et al (1980) Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn 27:521–525

    PubMed  CAS  Google Scholar 

  94. Delle Fave GF, Tamburrano G, de Magistris L et al (1977) Gynaecomastia with cimetidine. Lancet 1:1319. Medline. doi:10.1016/S0140-6736(77)91358-7

    Article  PubMed  CAS  Google Scholar 

  95. Petrillo M, Parada A, Porro GB et al (1977) Plasma prolactin and cimetidine. Lancet 2:761. Medline. doi:10.1016/S0140-6736(77)90260-4

    Article  PubMed  CAS  Google Scholar 

  96. Spiegel AM, Lopatin R, Peikin S et al (1978) Serum prolactin in patients receiving chronic oral cimetidine. Lancet 1:881. MEdline. doi:10.1016/S0140-6736(78)90229-5

    Article  PubMed  CAS  Google Scholar 

  97. Majumdar SK, Thomson AD, Shaw GK (1978) Cimetidine and serum prolactin. BMJ 1:409–410. Medline

    PubMed  CAS  Google Scholar 

  98. Scarpignato C, Bertaccini G (1979) Cimetidine and endocrine secretions: a short review. Drugs Exp Clin Res 5:129–140

    CAS  Google Scholar 

  99. Lombardo L (1983) More about ranitidine and hyperprolactinaemia. Lancet 2:42–43. Medline. doi:10.1016/S0140-6736(83)90022-3

    Article  PubMed  CAS  Google Scholar 

  100. Carlson HE, Ippoliti AF, Swerdloff RS (1981) Endocrine effects of acute and chronic cimetidine administration. Dig Dis Sci 26:428–432. Medline. doi:10.1007/BF01313585

    Article  PubMed  CAS  Google Scholar 

  101. Delpre G, Lapidot M, Lipchitz A et al (1993) Hyperprolactinaemia during famotidine therapy. Lancet 342:868. Medline. doi:10.1016/0140-6736(93)92729-D

    Article  PubMed  CAS  Google Scholar 

  102. Hutchinson J, Murphy M, Harries R et al (2000) Galactorrhea and hyperprolactinemia associated with protease inhibitors. Lancet 356:1003–1004. Medline. doi:10.1016/S0140-6736(00)02697-0

    Article  PubMed  CAS  Google Scholar 

  103. Montero A, Bottasso OA, Luraghi MR et al (2001) Galactorrhoea, hyperprolactinaemia, and protease inhibitors. Lancet 357:473–474. MEdline. doi:10.1016/S0140-6736(05)71275-7

    Article  PubMed  CAS  Google Scholar 

  104. Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 34:99–116. doi:10.1016/j.ecl.2005.09.011

    Article  Google Scholar 

  105. Reyniak JV, Wenof M, Aubert JM et al (1980) Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 55:8–11. Medline

    PubMed  CAS  Google Scholar 

  106. Luciano AA, Sherman BM, Chapler FK et al (1985) Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65:506. Medline

    PubMed  CAS  Google Scholar 

  107. Abu-Fadil S, DeVane G, Siler TM et al (1976) Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 13:79–95. Medline. doi:10.1016/0010-7824(76)90076-7

    Article  PubMed  CAS  Google Scholar 

  108. Davis JRE, Selby C, Jeffcoate WJ (1984) Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427–434. Medline

    Article  CAS  Google Scholar 

  109. Hwang PLH, Ng CSA, Cheong ST (1986) Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 24:127–133. Medline

    Article  CAS  Google Scholar 

  110. Josimovich JB, Lavenhar MA, Devanesan MM et al (1987) Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 47:785–791. Medline

    PubMed  CAS  Google Scholar 

  111. DeLeo V, Lanzetta D, Vanni AL et al (1991) Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 44:155–161. Medline. doi:10.1016/0010-7824(91)90115-V

    Article  CAS  Google Scholar 

  112. Grasso A, Baraghini F, Barbieri C et al (1982) Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 4:19–26. Medline. doi:10.1016/0378-5122(82)90015-9

    Article  PubMed  CAS  Google Scholar 

  113. Perrone G, Falaschi P, Capri O et al (1994) Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 39:202–207. Medline

    PubMed  CAS  Google Scholar 

  114. Castel-Branco C, Martínez de Osaba MJ, Fortuny A et al (1995) Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison J Reprod Med 40:556–560. Medline

    Google Scholar 

  115. Foth D, Römer T (1997) Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 44:124–126. Medline

    PubMed  CAS  Google Scholar 

  116. Schlegel W, Petersdorf LI, Juner R et al (1999) The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women. Clin Endocrinol (Oxf) 51:643–651. Medline. doi:10.1046/j.1365-2265.1999.00857.x

    Article  CAS  Google Scholar 

  117. Matzkin H, Haver I, Lewyshon O et al (1988) The role of increased prolactin levels under GnRH analogue treatment in advanced prostate carcinoma. Cancer 61:2187–2191. Medline. doi:10.1002/1097-0142(19880601)61:11<2187::AID-CNCR2820611109>3.0.CO;2-7

    Article  PubMed  CAS  Google Scholar 

  118. Siegel YI, Korczak D, Lindner A (1991) Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 19:16–18. Medline

    PubMed  CAS  Google Scholar 

  119. Kauschansky A, Nussinovitch M, Frydman M et al (1995) Hyperprolactinemia after treatment of long-acting gonadotropin-releasing analogue Decapetyl in girls with central precocious puberty. Fertil Steril 64:285–287. Medline

    PubMed  CAS  Google Scholar 

  120. Massart F, Parrino R, Placidi G et al (2005) Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children. Fertil Steril 84:719–724. Medline. doi:10.1016/j.fertnstert.2005.03.041

    Article  PubMed  CAS  Google Scholar 

  121. Molitch ME, Reichlin S (1985) Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin basic and clinical correlates. Liviana Press, Padova, Italy, pp 709–719

    Google Scholar 

  122. Bevan JS, Burke CW, Esiri MM et al (1987) Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 82:29–32. Medline. doi:10.1016/0002-9343(87)90373-1

    Article  PubMed  CAS  Google Scholar 

  123. Arafah BM, Neki KE, Gold RS et al (1995) Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 80:3507–3512. Medline. doi:10.1210/jc.80.12.3507

    Article  PubMed  CAS  Google Scholar 

  124. Naidich MJ, Russell EJ (1999) Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 28:45–79. doi:10.1016/S0889-8529(05)70057-8

    Article  CAS  Google Scholar 

  125. Takahashi H, Higuchi H, Kamata M et al (2003) Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsyc Clin Neurosci 15:375–377

    CAS  Google Scholar 

  126. Keller R, Mongini F (2002) Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 23:233–235. Medline. doi:10.1007/s100720200047

    Article  PubMed  CAS  Google Scholar 

  127. Lee B-H, Kim Y-K, Park S-H (2006) Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30:714–717. doi:10.1016/j.pnpbp.2006.02.001

    Article  PubMed  CAS  Google Scholar 

  128. Kinon BJ, Ahl J, Liu-Seifert H et al (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588. Medline. doi:10.1016/j.psyneuen.2005.12.006

    Article  PubMed  CAS  Google Scholar 

  129. Tschoner A, Engl J, Laimer M et al (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61:1356–1370. Medline. doi:10.1111/j.1742-1241.2007.01416.x

    Article  PubMed  CAS  Google Scholar 

  130. Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W (1975) Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry 126:285–288. Medline

    Article  PubMed  CAS  Google Scholar 

  131. Cohen JB, Brust J, DiSerio F, Singer J (1985) Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 13:173–179. Medline

    Article  Google Scholar 

  132. Smith J (1992) Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 37:737–740. Medline

    PubMed  CAS  Google Scholar 

  133. Tollin SR (2000) Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23:765–770. Medline

    PubMed  CAS  Google Scholar 

  134. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E (2004) Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187–190. Medline

    Article  PubMed  CAS  Google Scholar 

  135. Glassner-Cohen L, Biederman J (2001) Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adol Psychopharmacol 11:435–440. doi:10.1089/104454601317261618

    Article  Google Scholar 

  136. Frye PE, Pariser SF, Kim MH et al (1982) Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 43:252–253. Medline

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Disclosure

The author is currently receiving research support from Sanofi-Aventis Pharmaceuticals, Tercica, Inc., Ardana, Inc. and Amgen, Inc. and is serving as a consultant to Abbott Laboratories and Merck.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue (Tarry 15-731), Chicago, IL, 60611, USA

    Mark E. Molitch

Authors
  1. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Molitch.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Molitch, M.E. Drugs and prolactin. Pituitary 11, 209–218 (2008). https://doi.org/10.1007/s11102-008-0106-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-008-0106-6

Keywords

search

Navigation